Publication
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (12)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 12
- cancerCutaneous Melanomacivic_curation1.00
- cancerMelanomacivic_curation1.00
- cancerUveal Melanomacivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- geneGNA11civic_curation1.00
- geneGNAQcivic_curation1.00
- geneNRAScivic_curation1.00
- variantBRAF L597Vcivic_curation1.00
- variantGNA11 Mutationcivic_curation1.00
- variantGNAQ Mutationcivic_curation1.00
- variantNRAS Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22805292
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF L597V1 | ||||||||
| Trametinib | Cutaneous MelanomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1463Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response wi… (full text at CIViC) PMID 22805292 · Falchook et al., 2012 · Open in CIViC | civic |
| NRAS Mutation1 | ||||||||
| Trametinib | Melanoma | Predictive | B | Does Not Support Sensitivity Response | 2 | accepted | EID1227Phase 1 trial in 97 patients with melanoma (81 cutaneous or unknown, 16 uveal). Seven patients were found to harbor an NRAS mutation and two of them experienced stable disease (one 48 weeks on treatme… (full text at CIViC) PMID 22805292 · Falchook et al., 2012 · Open in CIViC | civic |
| GNA11 Mutation1 | ||||||||
| Trametinib | Uveal Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1228Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and t… (full text at CIViC) PMID 22805292 · Falchook et al., 2012 · Open in CIViC | civic |
| GNAQ Mutation1 | ||||||||
| Trametinib | Uveal Melanoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1229Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and t… (full text at CIViC) PMID 22805292 · Falchook et al., 2012 · Open in CIViC | civic |